Effect of Hyperuricaemia on Chronic Renal Disease

Xuzhou Medical University

Status and phase: Unknown; Phase 4

Conditions: Chronic Renal Disease; Hyperuricemia

Treatments: Drug: 40mg Febuxostat; Drug: 20mg Febuxostat

Study type: Interventional

Funder types: Other

Identifiers

NCT03425708

XYFY2017-KL043-01

Details and patient eligibility

About

To investigate the Effect of Hyperuricaemia on Chronic Renal Disease and Intervention

Full description

This study aims to explore the best effective dose and adverse reaction of febuxostat in lowering serum uric acid to low level in patients with Chronic Renal Disease at different stages. To elucidate that low levels of serum uric acid can delay the progression of renal damage. Promote the application of anti uric acid drugs in the treatment of chronic renal failure and delay the progress of CKD in patients

Enrollment: 400 estimated patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Non-dialysis CKD patients with serum uric acid greater than 7mg/dl.
• eGFR≥15ml/min/1.73m².
• Low salt, low protein, low purine diet.

Exclusion criteria

• Take drugs that raise blood uric acid at the same time.
• Patients with gout attacks.
• Patients with pregnant, lactating.
• Autosomal dominant polycystic kidney disease.
• Patients with poor general condition and multiple organ failure.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

400 participants in 3 patient groups

Treatment group1

Active Comparator group

Description:

Febuxostat pill 20mg was used to treat CKD patients with hyperuricaemia.

Treatment:

Drug: 20mg Febuxostat

Treatment group2

Active Comparator group

Description:

Febuxostat pill 40mg was used to treat CKD patients with hyperuricaemia.

Treatment:

Drug: 40mg Febuxostat

Control group

No Intervention group

Description:

Treatment of CKD patients with hyperuricaemia with conventional methods.